Media headlines about Dicerna Pharmaceuticals (NASDAQ:DRNA) have been trending positive recently, AlphaOne reports. The research firm, a service of Accern, ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Dicerna Pharmaceuticals earned a news sentiment score of 0.31 on AlphaOne’s scale. AlphaOne also assigned headlines about the biopharmaceutical company an impact score of 50 out of 100, meaning that recent media coverage is somewhat likely to have an impact on the stock’s share price in the immediate future.

DRNA has been the topic of several analyst reports. Zacks Investment Research cut Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, March 24th. Cowen and Company reaffirmed a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Tuesday, May 9th. Jefferies Group LLC reaffirmed a “buy” rating and set a $7.00 target price (down previously from $8.00) on shares of Dicerna Pharmaceuticals in a research note on Sunday, April 2nd. Finally, HC Wainwright cut their target price on Dicerna Pharmaceuticals from $8.00 to $5.00 and set a “buy” rating on the stock in a research note on Monday, April 10th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $5.88.

Shares of Dicerna Pharmaceuticals (NASDAQ DRNA) traded down 2.27% on Wednesday, reaching $3.02. The company had a trading volume of 56,936 shares. The company’s 50 day moving average price is $3.15 and its 200-day moving average price is $2.99. The stock’s market capitalization is $62.80 million. Dicerna Pharmaceuticals has a 1-year low of $2.42 and a 1-year high of $6.10.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by $0.03. Dicerna Pharmaceuticals had a negative net margin of 10,677.44% and a negative return on equity of 162.06%. The company had revenue of $0.13 million during the quarter, compared to analyst estimates of $0.08 million. Equities analysts predict that Dicerna Pharmaceuticals will post ($2.31) EPS for the current year.

WARNING: This article was first published by Daily Political and is the property of of Daily Political. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Receive News & Ratings for Dicerna Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc and related companies with's FREE daily email newsletter.